If I had $10,000 ready to invest in Australian shares right now, I would be looking for companies with strong global businesses.
Ideally, they would also be businesses that have recently fallen out of favour with the market.
Short term share price weakness can sometimes create opportunities to buy high-quality companies at far more attractive prices.
Right now, two ASX stocks stand out to me as particularly interesting opportunities.
Here's why.
Image source: Getty Images
WiseTech Global Ltd (ASX: WTC)
The WiseTech share price is currently down 1.72% to $45.83.
That means the logistics software company has fallen more than 45% over the past year and about 33% since the start of 2026.
Despite this sharp decline, the underlying business remains one of the most dominant technology platforms in global logistics.
WiseTech is best known for its CargoWise platform, which helps freight forwarders and logistics providers manage complex global supply chains.
Once customers adopt the software, switching away can be extremely difficult. This creates strong recurring revenue and high margins.
The company recently reported revenue of US$672 million in the first-half of FY26, representing 76% growth compared with the same period a year earlier. EBITDA rose 31% to US$252 million.
Looking ahead, management expects FY26 revenue between US$1.39 billion and US$1.44 billion, with EBITDA forecast between US$550 million and US$585 million.
Another encouraging signal is insider buying.
Recent disclosures show several directors purchasing shares on market in February, including:
• Andrew Harrison buying 1,000 shares at $48.20
• Raelene Murphy buying 2,054 shares at $48.99
• Christopher Charlton buying 2,500 shares at $49.90
Director buying can often be a positive sign because company insiders are committing their own money.
After such a steep sell-off, WiseTech shares could rebound strongly if growth continues and sentiment improves.
CSL Ltd (ASX: CSL)
The CSL share price is currently down 0.44% to $140.04.
The biotechnology giant has also experienced a difficult run recently, with the stock falling roughly 43% over the past year.
This is unusual for a company that has historically been one of the ASX's most successful global healthcare businesses.
CSL operates through two major divisions.
CSL Behring develops plasma-based therapies used to treat serious medical conditions such as immune deficiencies and haemophilia.
Meanwhile Seqirus is one of the world's largest influenza vaccine providers.
Demand for plasma therapies continues to grow globally.
The company also maintains a strong pipeline of new treatments that could support future earnings growth.
Following the recent sell-off, some analysts believe the valuation now looks appealing.
One broker has maintained a 'buy' rating with a price target around $235, suggesting significant potential upside from current levels.
Foolish bottom line
Both WiseTech and CSL remain globally competitive businesses despite their recent share price weakness.
If I had $10,000 to invest today, I would consider splitting it evenly between these two companies.
